載入...
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
BACKGROUND: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster head...
Na minha lista:
| 發表在: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7222235/ https://ncbi.nlm.nih.gov/pubmed/32426040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420918088 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|